- Aust Prescr 2005;28:49-55
- 1 June 2005
- DOI: 10.18773/austprescr.2005.062
Some of the views expressed in the following notes on newly approved products should be regarded as preliminary, as there may have been limited published data at the time of publication, and little experience in Australia of their safety or efficacy. However, the Editorial Executive Committee believes that comments made in good faith at an early stage may still be of value. Before new drugs are prescribed, the Committee believes it is important that more detailed information is obtained from the manufacturer's approved product information, a drug information centre or some other appropriate source.
Irinotecan (Mayne Pharma)
vials containing 40 mg/2 mL and 100 mg/5 mL for injection